In the year 1546, the first official pharmacopoeia appeared in Germany and the profession of pharmaceuticals is stated to have begun in the year 1617 in the town of London with the formation of Society of Apothecaries. Since then the pharmaceutical Industry has come a long way due to the unification of fields of chemistry and physiology led to a better understanding of the drug creating process.


Pharmaceuticals are substances which are used in the diagnosis, treatment, prevention of diseases and for restoring, correcting or modifying organic functions. Pharmaceuticals are generally classified by the chemical group, the way they work in the body (the pharmacological effect) and by the therapeutic use. The pharmaceuticals industry is aimed at discovery, development and production, as well as pharmaceuticals drugs for use as medication for patients to be administered or self-administered to cure them, alleviate or vaccinate them. Due to a rapid growth in chronic and infectious diseases, the global pharmaceutical market is growing at an exceptional rate leading to a rise in life expectancy of people all around the world. All the pharmaceuticals companies are governed by certain laws and regulations that govern the patenting, the testing, safety, efficiency and marketing of the drugs and medication the companies endorse or produce. To keep up with the rise in competitive market of pharmaceuticals, the leading players in the industry divert as much as around 10% of their turnover profits to their research departments. At MIR, our analysts go through the rapid changing marketing scenarios in the pharmaceuticals industry to gain the latest knowledge and insights. This helps us create the best analytical reports in the markets helping us predict a much accurate forecasts in the upcoming years for the pharmaceuticals market.

healthcare
Biosimilars Market by Product (Recombinant Glycosylated Proteins (Monoclonal Antibodies (Rituximab, Adalimumab, and Infliximab), Erythropoietin, and Follitropin), Recombinant Non-Glycosylated Proteins (Insulin, Granulocyte Colony Stimulating Factor, Recombinant Human Growth Hormone and Interferon (Interferon-Alpha and Interferon-Beta)), Recombinant Peptides (Glucagon and Calcitonin)), Type of Manufacturing (In-house Manufacturing, and Contract Manufacturing), Disease (Chronic Disease , Oncology, Autoimmune Disease, Blood disorders, Infectious Diseases, and Growth Hormone Deficiency) - Global Forecast to 2030

Biosimilars Market Overview and Introduction

Biosimilars are bio-medical products that are identical copies of an original pharmaceutical drug, which has been manufactured by a different manufacturing company. Biosimilars are manufactured once the patent of the original product expires. Unlike generic drugs, biosimilars exhibit high molecular complexity and are sensitive to alterations in the processes of manufacturing. These drugs are similar to reference product

Published :Apr 2019   |   Pages : 150   |   Price starts from : $5100

healthcare
Alzheimer’s Drugs Market by Drug Class (Cholinesterase Inhibitors (Donepezil, Galantamine, Rivastigmine), NMDA Receptor Antagonists (Memantine)), by Distribution Channel (Direct Distribution Channel, Indirect Distribution Channel) - Analysis & Forecast 2019-2030

Alzheimer’s Drugs Market Overview and Introduction

Alzheimer’s disease is a progressive brain disorder, in which the brain gradually degenerates resulting in loss of memory, brain dysfunction, and cellular loss. It most often occurs in people aged above 65–70 years. A person afflicted with Alzheimer’s also has to encounter issues with reasoning or judgment, steady decline in the ability to perform routine tasks, difficulty in learning,

Published :Apr 2019   |   Pages : 150   |   Price starts from : $5100